Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dipyridamole
Drug ID BADD_D00692
Description A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
Indications and Usage For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
Marketing Status Prescription; Discontinued
ATC Code B01AC07
DrugBank ID DB00975
KEGG ID D00302
MeSH ID D004176
PubChem ID 3108
TTD Drug ID D0F9GE
NDC Product Code 62559-236; 64980-133; 0115-1070; 62559-237; 69584-182; 65841-664; 64980-135; 65404-005; 65015-782; 65841-662; 51407-628; 0115-1071; 0527-1461; 51662-1447; 69584-183; 65841-663; 62559-235; 0641-2569; 0527-1463; 51407-626; 68166-003; 0404-9852; 66039-917; 0527-1462; 71205-894; 52584-569; 51927-1571; 51407-627; 70896-2025; 68382-187; 0115-1072; 68382-188; 68382-189; 12660-0084; 69584-181; 17511-122; 64980-134; 71205-896; 71205-895
Synonyms Dipyridamole | Dipyramidole | Apo-Dipyridamole | Apo Dipyridamole | Cerebrovase | Persantine | Persantin | Curantil | Curantyl | Kurantil | Miosen | Novo-Dipiradol | Novo Dipiradol | Antistenocardin | Cléridium
Chemical Information
Molecular Formula C24H40N8O4
CAS Registry Number 58-32-2
SMILES C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Generalised tonic-clonic seizure17.12.01.002--Not Available
Haemoglobin13.01.05.018--Not Available
Headache17.14.01.0010.015658%
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.004--Not Available
Hydrocephalus17.07.01.0010.004474%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.0020.001167%
Immune system disorder10.02.01.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.0020.004085%Not Available
Injection site pain08.02.03.010; 12.07.03.011--Not Available
Injection site reaction08.02.03.014; 12.07.03.015--
Intermittent claudication24.04.03.001--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Laryngospasm22.04.02.002--
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Menopausal symptoms21.02.02.002--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Muscle spasms15.05.03.004--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.0010.015658%
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages